300723 一品红
已收盘 01-14 15:00:00
资讯
新帖
简况
一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元
证券之星 · 01-14 19:39
一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元
股市必读：一品红（300723）1月12日董秘有最新回复
证券之星 · 01-13 01:38
股市必读：一品红（300723）1月12日董秘有最新回复
一品红：2024年员工持股计划持股5,116,105股
证券之星 · 01-12 16:48
一品红：2024年员工持股计划持股5,116,105股
一品红：2024年员工持股计划第一个解锁期解禁股票并未减持
证券之星 · 01-09
一品红：2024年员工持股计划第一个解锁期解禁股票并未减持
股市必读：一品红（300723）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：一品红（300723）1月8日董秘有最新回复
一品红：布局分子胶领域投资分迪药业和达歌生物
证券之星 · 01-08
一品红：布局分子胶领域投资分迪药业和达歌生物
股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%
证券之星 · 01-07
股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%
一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%
证券之星 · 01-05
一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%
1月5日一品红涨6.83%，广发医疗保健股票A基金重仓该股
证券之星 · 01-05
1月5日一品红涨6.83%，广发医疗保健股票A基金重仓该股
每周股票复盘：一品红（300723）拟出售美国Arthrosi公司股权
证券之星 · 01-03
每周股票复盘：一品红（300723）拟出售美国Arthrosi公司股权
股市必读：一品红（300723）12月30日董秘有最新回复
证券之星 · 2025-12-31
股市必读：一品红（300723）12月30日董秘有最新回复
一品红：阿尔法分子AM-001获中美临床许可
证券之星 · 2025-12-30
一品红：阿尔法分子AM-001获中美临床许可
一品红（300723）披露2026年度日常关联交易预计，12月29日股价下跌0.8%
证券之星 · 2025-12-29
一品红（300723）披露2026年度日常关联交易预计，12月29日股价下跌0.8%
一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%
证券之星 · 2025-12-23
一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%
一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书
智通财经 · 2025-12-23
一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书
一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%
证券之星 · 2025-12-22
一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%
一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展
证券之星 · 2025-12-22
一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展
一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%
证券之星 · 2025-12-18
一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%
一品红：公司高度重视市值管理
证券之星 · 2025-12-18
一品红：公司高度重视市值管理
【机构调研记录】景顺长城基金调研扬农化工、一品红
证券之星 · 2025-12-17
【机构调研记录】景顺长城基金调研扬农化工、一品红
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":41.75,"timestamp":1768374195000,"preClose":42.65,"halted":0,"volume":40087782,"delay":0,"changeRate":-0.0211,"floatShares":418000000,"shares":451999999,"eps":-0.9511,"marketStatus":"已收盘","change":-0.9,"latestTime":"01-14 15:00:00","open":43.34,"high":45.88,"low":41.56,"amount":1745000000,"amplitude":0.1013,"askPrice":41.76,"askSize":17,"bidPrice":41.75,"bidSize":937,"shortable":0,"etf":0,"ttmEps":-0.9511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":42.65,"symbolType":"stock","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":46.92,"lowLimit":38.39,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":11,"roa":"--","roe":"--","epsLYR":-1.1956,"committee":0.809496,"marketValue":18858000000,"turnoverRate":0.096,"status":1,"floatMarketCap":17438000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2603188736","title":"一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603188736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603188736?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:39","pubTimestamp":1768390789,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)发布业绩预告，预计2025年净利润亏损3.13亿元—4.42亿元，上年同期亏损5.4亿元。报告期，公司产品销售及毛利率水平有一定程度下降，加上公司广东瑞石创新原料药生产基地投入使用导致折旧摊销增加及研发持续投入，影响了公司经营业绩。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400036293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2603408315","title":"股市必读：一品红（300723）1月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603408315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603408315?lang=zh_cn&edition=full","pubTime":"2026-01-13 01:38","pubTimestamp":1768239489,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，一品红报收于37.46元，上涨0.27%，换手率3.34%，成交量13.96万手，成交额5.16亿元。董秘最新回复投资者： 最近成交量萎缩，股价也前置不前，一般横盘久了，会继续下跌，贵公司后期还有什么可以支撑股价的措施吗董秘： 尊敬的投资者您好，感谢您对公司的关注。当日关注点来自交易信息汇总：1月12日主力资金净流出1712.07万元，散户资金净流入3886.42万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2602979295","title":"一品红：2024年员工持股计划持股5,116,105股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602979295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602979295?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:48","pubTimestamp":1768207701,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司股权激励没有减持，那股本股东显示为什么2025年9月30号退出前10大流通股？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司2024年员工持股计划共持有5,116,105股公司股票，根据公司2025年第三季度报告（截至2025年9月30号），为公司第8大股东。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200021649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2602204345","title":"一品红：2024年员工持股计划第一个解锁期解禁股票并未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2602204345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602204345?lang=zh_cn&edition=full","pubTime":"2026-01-09 11:48","pubTimestamp":1767930486,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司股权激励第一期解禁的股票，又进入二级市场了吗？为什么占比达到了1%不进行公告？一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止2026年1月8日，公司2024年员工持股计划第一个解锁期解禁股票并未减持股票。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900015896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2602212392","title":"股市必读：一品红（300723）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602212392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602212392?lang=zh_cn&edition=full","pubTime":"2026-01-09 02:49","pubTimestamp":1767898148,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，一品红报收于36.02元，上涨1.78%，换手率2.82%，成交量11.77万手，成交额4.26亿元。董秘最新回复投资者： 董秘，您好！2021年5月，公司参股投资了专注于PROTAC领域的创新药研发企业分迪药业，其一家专注于“靶向蛋白降解剂-分子胶”创新药物研发的公司，主要致力于治疗癌症和病毒感染性疾病的分子胶创新药的开发。达歌生物已与武田、默沙东达成研发合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2601355001","title":"一品红：布局分子胶领域投资分迪药业和达歌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2601355001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601355001?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:30","pubTimestamp":1767857456,"startTime":"0","endTime":"0","summary":"据悉贵公司同时参与分迪药业和达歌生物的融资，且两家公司同处于“分子胶”这个赛道，背后的投资逻辑是什么？2021年5月，公司参股投资了专注于PROTAC领域的创新药研发企业分迪药业，其一家专注于“靶向蛋白降解剂-分子胶”创新药物研发的公司，主要致力于治疗癌症和病毒感染性疾病的分子胶创新药的开发。达歌生物已与武田、默沙东达成研发合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800018977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2601173814","title":"股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601173814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601173814?lang=zh_cn&edition=full","pubTime":"2026-01-07 01:43","pubTimestamp":1767721390,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，一品红报收于35.89元，上涨0.14%，换手率2.38%，成交量9.95万手，成交额3.57亿元。来自：截至2025年12月31日，公司股东户数达2.65万户，较前一期增长30.22%，户均持股数量下降至1.7万股。股本股东变化股东户数变动近日一品红披露，截至2025年12月31日公司股东户数为2.65万户，较11月30日增加6154.0户，增幅为30.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700000781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2601007217","title":"一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007217","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007217?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:00","pubTimestamp":1767607237,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，一品红报收于35.84元，较前一交易日上涨6.83%，最新总市值为161.89亿元。该股当日开盘33.53元，最高36.15元，最低33.2元，成交额达5.52亿元，换手率为3.75%。近日，一品红发布关于回购公司股份的进展公告。公告显示，公司于2025年12月15日召开董事会，审议通过回购公司股份方案，拟使用自有资金及/或自筹资金以集中竞价方式回购A股股份，用于维护公司价值及股东权益。回购实施符合相关规定，后续将根据市场情况继续推进回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2601006301","title":"1月5日一品红涨6.83%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006301?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:45","pubTimestamp":1767599154,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日一品红涨6.83%，收盘报35.84元，换手率3.75%，成交量15.64万手，成交额5.52亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为51.85亿元，最新净值1.755，较上一交易日下跌0.31%，近一年上涨8.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2600627320","title":"每周股票复盘：一品红（300723）拟出售美国Arthrosi公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2600627320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600627320?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:09","pubTimestamp":1767377350,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，一品红报收于33.55元，较上周的34.79元下跌3.56%。本周关注点公司公告汇总：一品红拟出售参股公司美国Arthrosi公司股权，相关议案将提交股东会审议。公司公告汇总：一品红将于2026年1月14日召开第一次临时股东会，审议重大事项。会议审议《关于拟出售参股公司美国Arthrosi公司股权的议案》和《关于2026年度日常关联交易预计的议案》，其中第二项议案涉及关联股东回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2595719770","title":"股市必读：一品红（300723）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595719770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595719770?lang=zh_cn&edition=full","pubTime":"2025-12-31 01:42","pubTimestamp":1767116533,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，一品红报收于34.11元，下跌1.16%，换手率1.88%，成交量7.87万手，成交额2.69亿元。公司公告汇总第四届董事会第十六次会议决议公告一品红药业集团股份有限公司于2025年12月29日召开第四届董事会第十六次会议，审议通过《关于2026年度日常关联交易预计的议案》，预计2026年度公司及子公司与关联方发生日常关联交易总额不超过10,435.00万元。股权登记日为2026年1月8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100001434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2595767097","title":"一品红：阿尔法分子AM-001获中美临床许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2595767097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595767097?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:15","pubTimestamp":1767082510,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红12月30日在投资者关系平台上答复投资者关心的问题。请问贵公司参股的分迪药业和阿尔法分子在创新药研发方面有没有什么进展？上半年，阿尔法分子申报的小分子AM-001 同时获批中国药监局和美国食品药监局临床许可IND药物临床试验批件。该产品为肥大细胞受体MRGPRX2调节剂，将用于特应性皮炎、荨麻疹等自身免疫系统疾病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000023252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2595735602","title":"一品红（300723）披露2026年度日常关联交易预计，12月29日股价下跌0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595735602?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:15","pubTimestamp":1767017723,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，一品红报收于34.51元，较前一交易日下跌0.8%，最新总市值为155.88亿元。该股当日开盘34.51元，最高34.78元，最低34.13元，成交额达3.23亿元，换手率为2.26%。公告显示，公司预计2026年度与关联方发生日常关联交易总金额不超过10,435.00万元。上述交易以市场价格为定价依据，遵循公允、合理原则，不会对公司独立性造成影响。该事项尚需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900037552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593241566","title":"一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593241566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593241566?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:18","pubTimestamp":1766499513,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，一品红报收于35.5元，较前一交易日下跌3.14%，最新总市值为160.35亿元。该股当日开盘36.8元，最高37.85元，最低34.92元，成交额达7.26亿元，换手率为4.86%。公司近日发布公告称，其全资子公司广州市联瑞制药有限公司收到国家药品监督管理局签发的丙戊酸钠注射用浓溶液《药品注册证书》。药品有效期24个月，批准文号有效期至2030年12月15日。此次获批将丰富公司产品管线，增强慢病药领域竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593092467","title":"一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593092467","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593092467?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:55","pubTimestamp":1766476503,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于丙戊酸钠注射用浓溶液的《药品注册证书》。此次公司获得丙戊酸钠注射用浓溶液注册证书，标志着公司具备了在国内市场销售该规格药品的资格，将进一步丰富公司产品管线和产品品类，增强了公司在慢病药的竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2593486846","title":"一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593486846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593486846?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:54","pubTimestamp":1766397277,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，一品红报收于36.65元，较前一交易日上涨2.95%，最新总市值为165.55亿元。该事项构成关联交易，但属于公司单方面获得利益且不支付对价的情形，无需提交股东会审议。同日，公司召开第四届董事会第十五次会议，审议通过《关于收到控股股东支持公司发展承诺暨关联交易的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593855094","title":"一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2593855094","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593855094?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:44","pubTimestamp":1766396658,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司控股股东广东广润集团有限公司承诺，待Arthrosi Therapeutics,Inc.被并购交易完成后，将其子公司持有的Arthrosi 9.07%股权按照E轮投资后的净收益无偿给予公司，以支持公司研发创新发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200021992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2592710809","title":"一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592710809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592710809?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:47","pubTimestamp":1766051256,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，一品红报收于34.72元，较前一交易日上涨4.14%，最新总市值为156.83亿元。该股当日开盘33.61元，最高35.47元，最低33.35元，成交额达8.99亿元，换手率为6.24%。根据公司于近日发布的公告，一品红药业集团股份有限公司于2025年12月17日首次通过集中竞价方式回购公司股份，回购股份数量为706,000股，占公司总股本的0.16%。本次回购符合相关法律法规及公司既定回购方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2592207389","title":"一品红：公司高度重视市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592207389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592207389?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:15","pubTimestamp":1766042126,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红12月18日在投资者关系平台上答复投资者关心的问题。公司高重视市值管理和投资者关系管理工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800017567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2592304956","title":"【机构调研记录】景顺长城基金调研扬农化工、一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592304956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592304956?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930313,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月16日披露的机构调研信息，景顺长城基金近期对2家上市公司进行了调研，相关名单如下：1）扬农化工 调研纪要：当前农药行业整体仍处于周期调整阶段，供给充足制约价格上行，预计价格将在底部震荡。氟螨双醚登记待批，预计2026年推向市场。2）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700003926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","BK0188","300723","600486"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768423299667,"stockEarnings":[{"period":"1week","weight":0.1797},{"period":"1month","weight":0.1187},{"period":"3month","weight":-0.2243},{"period":"6month","weight":-0.3779},{"period":"1year","weight":1.4444},{"period":"ytd","weight":0.2444}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26517人(较上一季度增加30.22%)","perCapita":"15750股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}